Gemseki Inc.

We are pleased to announce that Yoshiharu ASANUMA, CEO of Gemseki Investment Inc., will be participating as a panelist in the first session of the World Alliance Forum Tokyo 2024 on this Thursday, October 10th. The session, 「真実の探求と未来への革新、見えない可能性を発掘せよ」, will focus on exploring future innovations and uncovering hidden possibilities, topics closely aligned with our mission at Gemseki.   Since 1999, the World Alliance Forum has been at the forefront of promoting public interest capitalism, emphasizing long-term, sustainable business strategies. We are honored to take part in this important dialogue and to share insights from our industry experience.   The event will be held both offline in Tokyo and broadcast online. We look forward to contributing to the discussions and gaining valuable perspectives from fellow industry leaders. For more information, please visit: https://www.waftokyo.com/ #WAF東京 #WAFTOKYO #LifeSciences #BiotechStartups #HealthcareInnovation #Biopharma #DrugDevelopment #VentureCapital #HealthcareLeadership #InnovationInHealth #FutureOfHealthcare #Pharmaceuticals

We’re excited to announce that Gemseki and SNBL will be exhibiting together at #BioJapan2024 from October 9th to 11th at PACIFICO YOKOHAMA. Visit us at Booth No. R-32, where we will showcase our comprehensive solutions, supporting everything from drug discovery to clinical development. With Gemseki's BD business now part of SNBL as a division, we provide a unified approach to solving your challenges, while investment support will be offered by Gemseki Investment Inc., a newly established subsidiary of the SNBL Group. This new entity manages the former VC business of Gemseki, leveraging our investment strategies to support growth. Whether you are seeking drug development assistance or looking for new partnerships and funding opportunities, our team will be on-site to assist. We look forward to seeing you there! https://jcd-expo.jp/en/ BioJapan / JTB Communication Design hashtag #BioJapan #LifeSciences #PharmaSupport #Gemseki #SNBL #DrugDiscovery #DrugDevelopment #Funding #VC #Licensing #BD #PharmaLicensing #InLicensing #Outlicensing #導入導出支援 #創薬シーズ #DrugCandidate #DrugCandidateMarketplace #薬市楽座 #GlobalPartnership

We are pleased to announce that, effective today, an important organizational restructuring has taken effect within our group. To further enhance management efficiency and strengthen our organizational foundation: ◾ SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (SNBL), our wholly owning parent company, will assume Gemseki’s business development (BD) operations. ◾ In addition, Gemseki Investment Inc., a newly established subsidiary wholly owned by SNBL, will succeed to Gemseki’s investment business. This strategic reorganization reflects our commitment to optimizing our operations and positioning ourselves for continued growth. For more information, please refer to the official press release (available in Japanese): https://lnkd.in/gpGChZYD.

[NEW ASSET LISTED] GEM327: AAV-based Gene Therapy ☑Gene replacement by rAAV8 delivery of a functional cytochrome P450 4v2 (CYP4V2) transgene via sub-retinal injection. ☑A total of 12 subjects were enrolled in phase 1/2 study, and the safety profile was favorable. ☑The study eye showed an average improvement of 3-4 lines in bestcorrected visual acuity (BCVA). ☑The expected initiation of Phase III is in H1 2025. ☑The product has BIC and FIC potential. Check out more details on our website https://lnkd.in/gt5E2mZm or message us if you're interested! #Gemseki #DrugCandidateMarketplace #Licensing #PharmaLicensing #Bio #InLicensing #OutLicensing #LicenseIn #LicenseOut #DrugCandidates #Technology #DrugDevelopment #BioScience #LifeSciences #LicensingPartnership #BioTech #pharmaceuticals #Partnerships #pharmaRD #GeneTherapy #Ophtalmology #RareDisease #BCD

[NEW ASSET LISTED] GEM322: Sustained relaese local anesthesia GEM322 is Ropivacaine Extended-release Injection. The originator has developed GEM322 based on PG-Depot and EFLA technology platform in order to prolong its duration at the local site, leading to an extended local analgesic effect. Advantages: - Safety of excipients, less systemic exposute of Ropivacaine - Extended pain relief - Reduction in opioid consumption - Non-addictive risk and good safety - Easy to use and cost-saving Check out more details on our website https://lnkd.in/gt5E2mZm or message us if you're interested! #Gemseki #DrugCandidateMarketplace #Licensing #PharmaLicensing #Bio #InLicensing #OutLicensing #LincenseIn #LicenseOut #DrugCandidates #Technology #DrugDevelopment #BioScience #LifeSciences #LicensingPartnership #BioTech #pharmaceuticals #Phartnerships #pharmaRD #SmallMolecule #Pain #Neuropathy #anesthesia

[NEW ASSET LISTED] TGEM077:Testing techniques for early detection of leukemia relapse - Whole genome analysis allows identification of all genetic mutations (single nucleotide and structural mutations) - Unique program identifies leukemia-causing gene mutations - Preparation of test reagents to detect causative gene mutations - Relapse monitoring can be done with a blood test instead of a bone marrow test - Relapse monitoring possible in 96% of leukemia patients - Data obtained from the test can be used for leukemia research and development Check out more details on our website https://lnkd.in/gt5E2mZm or message us if you're interested! #Gemseki #DrugCandidateMarketplace #Licensing #PharmaLicensing #Bio #InLicensing #OutLicensing #LincenseIn #LicenseOut #DrugCandidates #Technology #DrugDevelopment #BioScience #LifeSciences #LicensingPartnership #BioTech #pharmaceuticals #Phartnerships #pharmaRD #PlatformTechnology #Leukemia #LeukemiaRelapse #genetic

[NEW ASSET LISTED] GEM321:TME targeted Checkpoint Inhibitor (CPI) mAbs to Reinvigorate Exhausted Tumor-infiltrating T cells – CTLA4 Anti-CTLA4 antibody is an approved drug in the clinic. Ipilimmab is known to deplete Tregs and promote T cell priming, thus syngerise with anti-PD-1 antibody. While effective in some patients, anti-CTLA4 is more toxic than anti-PD-1. Ipilimumab reportedly does not deplete intratumor Tregs. With our tumour specific delivery with just recombinant fution of tumor-targeting (TT) domain, TT-anti-CTLA4 (GEM321) depletes intratumor Tregs very efficiently. Intravenous injection of GEMxxx induced >60% tumor free mice in orthotopic X-ray resistant glioblastoma mouse models. GEM321 was safer than conventional anti-CTLA4 antibody. Conventional anti-CTLA4 antibody does not have therapeutic effects at all in this mouse model. Check out more details on our website https://lnkd.in/gt5E2mZm or message us if you're interested! #Gemseki #DrugCandidateMarketplace #Licensing #PharmaLicensing #Bio #InLicensing #OutLicensing #LincenseIn #LicenseOut #DrugCandidates #Technology #DrugDevelopment #BioScience #LifeSciences #LicensingPartnership #BioTech #pharmaceuticals #Phartnerships #pharmaRD #Oncology #SolidCancer #Protein

We are thrilled to announce that our portfolio company, PRISM BioLab Co., Ltd., has successfully listed its shares on the Growth Market of the Tokyo Stock Exchange at July 2, 2024. This milestone reflects their potential and growth, and we are proud to stand alongside them as they achieve greater success.   PRISM BioLab, led by CEO Dai Takehara and based in Kanagawa, is a biotech company that leverages its unique PepMetics® technology to create new drug discovery fields for targets that were previously difficult to address. Their dual business model combines in-house development and collaborative development with major pharmaceutical companies, aiming for both stability and long-term profitability.   We remain committed to supporting PRISM BioLab as they continue to innovate and work towards developing new therapies for previously untreatable diseases.   Congratulations to PRISM BioLab on this significant achievement! 🎉 #Gemseki #PRISMBioLab #TokyoStockExchange #TSE #Biotech #Funding #VentureCapital #VC #Innovation #DrugDevelopment

[NEW ASSET LISTED] GEM320: TME targeted agonist to GITR (glucocorticoid-induced TNF receptor) Anti-GITR antibody depletes Tregs. Anti-GITR antibody was tested by >5 different companies in the clinic. They found that anti-GITR antibody is safe but not efficacious against cancer. With our tumour specific delivery with just recombinant fution of tumor-targeting (TT) domain, TT-anti-GITR (GEM320) depletes intratumor Tregs very efficiently. GEM320 localized inside the tumor, while conventional GITR antibody did not. Intravenous injection of GEM320 induced >65% tumor free mice in orthotopic X-ray resistant glioblastoma mouse models when conbined with anti-PD-1 antibody. GEM320 monotherapy induced >15% tumor free mice in this GBM model. Conventional anti-GITR antibody does not have therapeutic effects at all in this mouse model. Check out more details on our website https://lnkd.in/gt5E2mZm or message us if you're interested! #Gemseki #DrugCandidateMarketplace #Licensing #PharmaLicensing #Bio #InLicensing #OutLicensing #LincenseIn #LicenseOut #DrugCandidates #Technology #DrugDevelopment #BioScience #LifeSciences #LicensingPartnership #BioTech #pharmaceuticals #Phartnerships #pharmaRD #Oncology #SolidCancer #Protein

[NEW ASSET LISTED] GEM319: Cartilage regeneration, pain control and anti-inflammation by UCB-MSCs with CAM  ・Allogenic human umbilical cord blood (UCB)-derived MSC with cartilage acellular matrix (CAM) for the treatment of K&L Grade 2 - 3 OA patients. ・Single intra-articular (IA) injection shows DMOAD effects of structural improvement, pain relief and anti-inflammation. ・Administration of Phase 1 has been completed. Interim analysis showed excellent VAS pain relief and functional improvement. 6-month MRI image on knee cartilage will be obtained in Oct. 2024. ・Patent has been registered globally. Check out more details on our website https://lnkd.in/gt5E2mZm or message us if you're interested! #Gemseki #DrugCandidateMarketplace #Licensing #PharmaLicensing #Bio #InLicensing #OutLicensing #LincenseIn #LicenseOut #DrugCandidates #Technology #DrugDevelopment #BioScience #LifeSciences #LicensingPartnership #BioTech #pharmaceuticals #Phartnerships #pharmaBD #pharmaRD #Orthopedics #Immunology #Inflammation #Regenerative #Medicine #CellTherapy #KneeOsteoarthritis #injection #Patent